New drug JY016 targets tough cancers with EGFR marker in early trial
NCT ID NCT07510841
First seen Apr 12, 2026 · Last updated May 14, 2026 · Updated 6 times
Summary
This study tests a new drug called JY016 in 228 adults with advanced solid tumors that have a protein called EGFR. The trial has two parts: first, finding the safest dose, then testing how well it works against cancers like pancreatic, lung, and colon cancer. The goal is to control the disease, not cure it, and participants must have tried standard treatments without success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID CANCERS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.